Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Luquet

Showing results (11-20 of 61) with videos related to

Pageof 7
Sort By:
European Journal of Haematology|May 18, 2012
Therapy-related acute myeloid leukemia (t-AML) with poor-risk cytogenetics in two patients with persistent molecular complete remission of acute promyelocytic leukemiaMario Ojeda-Uribe, Anne Schneider, Isabelle Luquet, et al.
American Journal of Hematology|October 29, 2015
Impact of obesity in favorable-risk AML patients receiving intensive chemotherapySuzanne Tavitian, Amélia Denis, François Vergez, et al.
European Journal of Haematology|May 27, 2020
Dactinomycin in acute myeloid leukemia with NPM1 mutationsGuillaume Beziat, Suzanne Tavitian, Sarah Bertoli, et al.
Kidney International Reports|March 18, 2021
Kidney Involvement in Patients With Chronic Myelomonocytic Leukemia or BCR-ABL-Negative Myeloproliferative NeoplasmsJulie Belliere, Magali Colombat, Clément Kounde, et al.
Blood Cancer Journal|November 30, 2017
Improved outcome for AML patients over the years 2000-2014Sarah Bertoli, Suzanne Tavitian, Anne Huynh, et al.
Leukemia Research|September 15, 2017
Platelet transfusion refractoriness in patients with acute myeloid leukemia treated by intensive chemotherapyThibault Comont, Suzanne Tavitian, Laurent Bardiaux, et al.
Ejhaem|March 9, 2026
Selumetinib as an Effective Therapy of Histiocytic Sarcoma Evolving From a B-Cell Acute Lymphoblastic LeukaemiaLaetitia Largeaud, Charlotte Syrykh, Julie Vial, et al.
Annals of Hematology|July 12, 2011
Morphology, cytogenetics, and survival in myelodysplasia with del(20q) or ider(20q): a multicenter studyFrançois Mullier, Sylvie Daliphard, Richard Garand, et al.
Leukemia Research|May 6, 2019
Outcome of AML patients with IDH2 mutations in real world before the era of IDH2 inhibitorsLaetitia Largeaud, Emilie Bérard, Sarah Bertoli, et al.
Genes, Chromosomes & Cancer|May 13, 2021
Optical genome mapping, a promising alternative to gold standard cytogenetic approaches in a series of acute lymphoblastic leukemiasValentin Lestringant, Nicolas Duployez, Dominique Penther, et al.
Pageof 7

Showing results (11-20 of 61) with videos related to

Sort By:
Pageof 7
European Journal of Haematology|May 18, 2012
Therapy-related acute myeloid leukemia (t-AML) with poor-risk cytogenetics in two patients with persistent molecular complete remission of acute promyelocytic leukemiaMario Ojeda-Uribe, Anne Schneider, Isabelle Luquet, et al.
American Journal of Hematology|October 29, 2015
Impact of obesity in favorable-risk AML patients receiving intensive chemotherapySuzanne Tavitian, Amélia Denis, François Vergez, et al.
European Journal of Haematology|May 27, 2020
Dactinomycin in acute myeloid leukemia with NPM1 mutationsGuillaume Beziat, Suzanne Tavitian, Sarah Bertoli, et al.
Kidney International Reports|March 18, 2021
Kidney Involvement in Patients With Chronic Myelomonocytic Leukemia or BCR-ABL-Negative Myeloproliferative NeoplasmsJulie Belliere, Magali Colombat, Clément Kounde, et al.
Blood Cancer Journal|November 30, 2017
Improved outcome for AML patients over the years 2000-2014Sarah Bertoli, Suzanne Tavitian, Anne Huynh, et al.
Leukemia Research|September 15, 2017
Platelet transfusion refractoriness in patients with acute myeloid leukemia treated by intensive chemotherapyThibault Comont, Suzanne Tavitian, Laurent Bardiaux, et al.
Ejhaem|March 9, 2026
Selumetinib as an Effective Therapy of Histiocytic Sarcoma Evolving From a B-Cell Acute Lymphoblastic LeukaemiaLaetitia Largeaud, Charlotte Syrykh, Julie Vial, et al.
Annals of Hematology|July 12, 2011
Morphology, cytogenetics, and survival in myelodysplasia with del(20q) or ider(20q): a multicenter studyFrançois Mullier, Sylvie Daliphard, Richard Garand, et al.
Leukemia Research|May 6, 2019
Outcome of AML patients with IDH2 mutations in real world before the era of IDH2 inhibitorsLaetitia Largeaud, Emilie Bérard, Sarah Bertoli, et al.
Genes, Chromosomes & Cancer|May 13, 2021
Optical genome mapping, a promising alternative to gold standard cytogenetic approaches in a series of acute lymphoblastic leukemiasValentin Lestringant, Nicolas Duployez, Dominique Penther, et al.
Pageof 7